LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Cerrado

SectorSanidad

441.67 3.15

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

428.29

Máximo

448.06

Métricas clave
By Trading Economics
Ingresos	-160M 1B
Ventas	-240M 3B
P/B Media del Sector	26.049 49.888
BPA	4.47
Margen de beneficios	34.531
Empleados	6,400
EBITDA	-215M 1.1B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+31.42% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.9B 111B
Apertura anterior	438.52
Cierre anterior	441.67

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

124 / 344 Clasificación en Healthcare

Vertex Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 may 2026, 20:57 UTC

Ganancias

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 feb 2026, 21:47 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 nov 2025, 21:44 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 ago 2025, 00:05 UTC

Acciones populares

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 ago 2025, 21:21 UTC

Ganancias

Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 may 2026, 20:02 UTC

Ganancias

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 may 2026, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 may 2026, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 may 2026, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 may 2026, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 feb 2026, 21:13 UTC

Ganancias

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 feb 2026, 21:13 UTC

Ganancias

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 feb 2026, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 feb 2026, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 feb 2026, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 feb 2026, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 nov 2025, 21:05 UTC

Ganancias

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:02 UTC

Ganancias

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 nov 2025, 21:02 UTC

Ganancias

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 nov 2025, 21:02 UTC

Ganancias

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 nov 2025, 21:02 UTC

Ganancias

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 ago 2025, 20:44 UTC

Ganancias

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 ago 2025, 18:17 UTC

Ganancias

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 ago 2025, 15:25 UTC

Ganancias

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 ago 2025, 14:12 UTC

Ganancias

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 ago 2025, 11:27 UTC

Ganancias

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:55 UTC

Ganancias

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:36 UTC

Ganancias

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:18 UTC

Ganancias

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Comparación entre iguales

Cambio de precio

Vertex Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

31.42% repunte

Estimación a 12 Meses

Media 562.91 USD 31.42%

Máximo 641 USD

Mínimo 436 USD

De acuerdo con 25 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vertex Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

25 ratings

Comprar

Mantener

Vender

De acuerdo con 25 analistas que ofrecen calificaciones bursátiles a para Vertex Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

124 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.